Eden vs. Goby Meds: prices, fine print, and the honest verdict

Tirzepatide pricing

Eden: $408 a month all-in at the 10 mg maintenance basis, dose-scaled from a $348 entry, including the mandatory $99/mo membership. Goby Meds offers tirzepatide without a published price we could capture.

Semaglutide pricing

Only Eden publishes a semaglutide price here: Semaglutide runs $198 a month all-in. Goby Meds offers semaglutide without a published price.

Transparency

Eden: Source-verified (verified 2026-08-05); dispensing pharmacy not publicly named. Goby Meds: No price published (verified 2026-08-05); dispensing pharmacy not publicly named. In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.

Commitment & cancellation

Eden: membership auto-renews; membership auto-renews until cancelled; $99/mo membership recurs until cancelled. Goby Meds: unknown; not published.

Two ladders, side by side

Titration is where these pricing structures stop being abstractions: Eden scales $348 → ~$408 by 10 mg (titration lands between $1,392 and $1,632). A flat ladder makes dose decisions purely clinical; a scaled one attaches an invoice to every escalation — including the post-plateau bump from 10 to 12.5 mg that many patients eventually face. Full framework: the titration cost guide.

The semaglutide board

Only Eden fields a verified semaglutide price here — $198/month all-in (#8 of 19) — while Goby Meds publishes no semaglutide figure we could capture. For a buyer starting on the cheaper molecule with a likely upgrade later, single-molecule programs mean a future re-shop; dual-molecule ones price the whole arc.

The five normalizations, applied to this pair

1 · All-in, not advertised. Eden's ranked figure is $408 ($309 medication + $99 mandatory membership); Goby Meds publishes no figure to normalize. 2 · Maintenance basis. Eden scales from $348 to $408, and the 10 mg figure is the one ranked. 3 · Terms separated. Eden: standing $408, no prepaid tier — standing rates rank, prepaid effectives are labeled beside them. 4 · Evidence tiered. Eden: source-verified, read 2026-08-05; Goby Meds: no price published, read 2026-08-05. 5 · Pharmacy weighed. Eden names no pharmacy; Goby Meds names no pharmacy — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.

Fine print, itemized

Eden: a mandatory $99/mo membership folded into our all-in figure; membership auto-renews until cancelled. Goby Meds: no membership — the medication figure is the billed figure; not published; commitment: unknown. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.

Transparency, audited

Eden carries source-verified pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Goby Meds carries no price published pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.

Switching between them

The switch mechanics are symmetric: new intake, new script, new pharmacy, old plan cancelled in writing. Budget a shipping-gap week, confirm the destination program's price at your current dose (not its starter figure), and if the move is also a molecule change, loop the prescriber in per the switching guide.

Refills, shipping, and the week-to-week reality

Logistics decide more churn than price does, so put them on the record: Eden: shipping included; consultation included in membership; async visit model. Goby Meds: shipping unknown; consultation unknown. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.

Who should pick which

Pick Eden if its published terms happen to fit your state, format, or timing. Pick Goby Meds if you refuse membership fees on principle. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.

What verification would take

For Goby Meds, ranking would require: any published price at all, on a page we can capture and date; the dose structure (flat or scaled, with the 10 mg tier stated); the pharmacy's name, 503A/503B status, and state licensure; commitment and cancellation terms verbatim. We publish the checklist because the gap is fixable — providers that clear it get ranked on the same arithmetic as everyone else, and readers who ask these questions get the answers this page can't yet print.

If neither one fits

Widen the frame one step and the strongest adjacent options are MEDVi at $399 (flat, no membership); Remedy Meds at $399 (flat, no membership); Fridays at $359 (flat, no membership) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.

The brand benchmark both must beat

Neither program exists in a vacuum: FDA-approved Zepbound sits at $449/month at maintenance (LillyDirect or retail KwikPens, ~$350 on TrumpRx, ~$50 for newly eligible Medicare patients), and Wegovy at a flat $349. The cheaper of these two compounded options saves $492/year against the Zepbound benchmark — the number that has to justify accepting a not-FDA-reviewed product, per the full trade analysis. When a compounded quote drifts above ~$350, this benchmark starts winning the argument on its own.

The verdict

With incomplete published pricing on one or both sides, get current figures in writing before enrolling with either. Both records, with dates and sources, live in the pricing database.